---

Highlights of Deals in October 2024

 

1.     Sun Pharma inks licensing pact with Philogen for cancer medication.

2.     Alkem Laboratories, Sonnet BioTherapeutics to jointly develop & market diabetic peripheral neuropathy drug in India.

3.     Strides Pharma CDMO arm gets Rs 801 crore(US$96.51 Million) commitment from investors in pre-listing.

4.     Mankind Pharma completes Rs 13,768 crore (US$1.6 Billion) BSV acquisition.

5.     Abhay HealthTech acquires MNP Healthcare to expand footprint in OTC segment.

6.     Zerion Pharma and Hovione create joint venture.

7.     Lundbeck to acquire Longboard Pharmaceuticals.

8.     Goldman-backed drug developer Septerna raises US$288 Million in US IPO.

9.     Novartis to pay Monte Rosa US$150 Million upfront to develop a new class of drugs.

10.  AbbVie banks on Alzheimer's therapy with US$1.4 Billion buy of Aliada.

11.  GEMMABio partners with Fiocruz in US$100 Million gene therapy deal.

12.  Ono Pharma licenses ADCs from LigaChem.

 

Aagami Updates:

1.     Aagami CEO Dinesh Jain, has successfully completed his business trip to Japan and Korea, with over 35 meetings held with key decision-makers. The trip included BIO Japan and KDDF partnering event.

2.     The BIO Europe event is underway (Nov 4-6, digitally Nov 12-13), and we have over 30 one-to-one meetings scheduled. If you’d like to connect, please send us your meeting requests very soon!

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

1.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses. Also MPOX.

2.     Licensing: Several Biosimilars available for Partnering in Japan

a.     Denosumab (Prolia® & Xgeva®)

b.     Romiplostim (Nplate®) [ For immune thrombocytopenia (ITP) ]

c.     Teriparatide (Forteo®/Forsteo®) [ For Osteoporosis ]

d.     Liraglutide (Victoza®) [ For Diabetes ]

e.     Tocilizumab (Actemra®) [ For Rheumatoid arthritis (RA), Giant Cell Arteritis (GCA), Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), Active Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) and patients with coronavirus disease 2019 (COVID-19) receiving systemic corticosteroids and requiring supplemental oxygen or mechanical ventilation. ]

3.     Seeking Acquisition /JV – Clinical stage Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia [Second Human Trial (n=30) ongoing in AU].

4. Seeking Partnering: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – For 1) Depression and ALS 2) Anti-Obesity.

For Acquisition:

1.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.

2.     IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).

3.     Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

1. Seeking Investment: Human-derived, chimeric therapeutic peptide. Phase 2b stage in Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications.
2. Seeking US$3 million: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – 1. For Depression and ALS 2. Anti-Obesity.
3. Seeking US$4 million: Integrated Autoimmune company - Engineering Therapeutics to Block Pathogenic Autoantibodies

Hope you found the content useful. We welcome your feedback and queries.